#ESCCongress – Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease – New England Journal of Medicine (free)

Editorial by Dr. Eugene Braunwald: An Important Step for Thrombocardiology (free)

Commentaries: Cardiovascular Outcomes for People Using Anticoagulation Strategies – COMPASS – American College of Cardiology, Latest in Cardiology (free) AND COMPASS: Does Rivaroxaban Plus Aspirin Improve CV Outcomes in Patients With Stable Atherosclerotic Vascular Disease or PAD? – ACC News Story (free) AND Rivaroxaban, Aspirin, or Both in Stable Coronary Disease – Physician’s First Watch (free)

The primary outcome (composite of cardiovascular death, stroke, or myocardial infarction) occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (4.1% vs. 5.4% / Absolute risk difference = 1.3% / NNT = 76), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (3.1% vs. 1.9% / Absolute risk difference = 1.2 / NNH = 83).